The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents

The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents

This study was designed with the rational aim of discussing the emerging antidepressant agents that are likely to bring positive landmark, tremendous improvement and significant impact to the management of patients with depression disorders. It also elaborates on the Agomelatine paradox vis-a-vis th...

Full description

Bibliographic Details
Main Author:	Olumuyiwa John Fasipe
Format:	Article
Language:	English
Published:	Elsevier 2019-06-01
Series:	IBRO Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2451830118300608

Similar Items

Neuropharmacological classification of antidepressant agents based on their mechanisms of action
by: Olumuyiwa John Fasipe
Published: (2018-01-01)

Moving from the old monoaminergic theory toward the emerging hypothesis in the rational design of rapid-onset novel antidepressants
by: Olumuyiwa John Fasipe
Published: (2019-01-01)

DRUG REPOSITIONING: Revisiting the basic psychopharmacological mechanism of action for agomelatine and where it should be classified?
by: Olumuyiwa John Fasipe, et al.
Published: (2019-01-01)

Potentiation of Antidepressant Effects of Agomelatine and Bupropion by Hesperidin in Mice
by: Jegan Sakthivel Nadar, et al.
Published: (2018-01-01)

What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?
by: Petr Potměšil
Published: (2019-06-01)

Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?
by: Fornaro M, et al.
Published: (2014-05-01)

Novel Conformationally Constrained Analogues of Agomelatine as New Melatoninergic Ligands
by: Marouan Rami, et al.
Published: (2012-12-01)

The Changes of Expression and Methylation of Genes Involved in Oxidative Stress in Course of Chronic Mild Stress and Antidepressant Therapy with Agomelatine
by: Paulina Wigner, et al.
Published: (2020-06-01)

Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action
by: Srinivasan, Venkataramanujan, et al.
Published: (2012)

Agomelatine for postpartum depression and breastfeeding
by: Le Xiao
Published: (2021-06-01)

Agomelatine – pharmacological properties and use in psychiatric practice
by: Marcin Siwek, et al.
Published: (2019-06-01)

Optimization and improvement of the synthesis method of agomelatine
by: Lei LIU, et al.
Published: (2018-02-01)

Efficacy and tolerability of agomelatine in the treatment of depression
by: Plesničar BK
Published: (2014-05-01)

Agomelatine Efficacy in the Night Eating Syndrome
by: Walter Milano, et al.
Published: (2013-01-01)

Understanding the Mechanism of Antidepressant-Related Sexual Dysfunction: Inhibition of Tyrosine Hydroxylase in Dopaminergic Neurons after Treatment with Paroxetine but Not with Agomelatine in Male Rats
by: Yanira Santana, et al.
Published: (2019-01-01)

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
by: Chen JW, et al.
Published: (2018-02-01)

Recent advances and current trend in the pharmacotherapy of obesity
by: Olumuyiwa John Fasipe
Published: (2018-01-01)

Differential and paradoxical roles of new-generation antidepressants in primary astrocytic inflammation
by: Jia-Hui He, et al.
Published: (2021-02-01)

Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
by: Domenico De Berardis, et al.
Published: (2015-01-01)

The Antidepressant Agomelatine Improves Memory Deterioration and Upregulates CREB and BDNF Gene Expression Levels in Unpredictable Chronic Mild Stress (UCMS)-Exposed Mice
by: Esen Gumuslu, et al.
Published: (2014-01-01)

The Antidepressant Agomelatine Improves Memory Deterioration and Upregulates CREB and BDNF Gene Expression Levels in Unpredictable Chronic Mild Stress (UCMS)-Exposed Mice
by: Esen Gumuslu, et al.
Published: (2014-03-01)

Approaches to therapy for depressions in neurology: prospects for the use of agomelatine
by: D. V. Romanov, et al.
Published: (2018-12-01)

Alopecia associated with agomelatine use: a case report
by: Ibrahim Gundogmus, et al.
Published: (2018-01-01)

The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice
by: Domenico De Berardis, et al.
Published: (2013-06-01)

Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study
by: Ivanov SV, et al.
Published: (2014-04-01)

A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks
by: Sparshatt, A., et al.
Published: (2013)

Agomelatine is superior to melatonin in pain suppression: An experimental study
by: Ali Okan Yucel, et al.
Published: (2020-01-01)

Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo
by: He JY, et al.
Published: (2018-03-01)

Agomelatine: relief ensured at each and every stage of depression
by: Möller Hans-Jurgen
Published: (2010-04-01)

α2- and β2-Adrenoreceptor-Mediated Efficacy of the Atypical Antidepressant Agomelatine Combined With Gabapentin to Suppress Allodynia in Neuropathic Rats With Ligated Infraorbital or Sciatic Nerve
by: Saïd M’Dahoma, et al.
Published: (2018-06-01)

Differentiated approach and indications for optimization of agomelatine therapy for endogenous depression
by: L. I. Abramova, et al.
Published: (2019-06-01)

Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm
by: Liliana Civalleri, et al.
Published: (2012-09-01)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
by: Pecenak J, et al.
Published: (2013-10-01)

Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
by: Levitan MN, et al.
Published: (2015-05-01)

UV SPECTROPHOTOMETRIC METHOD FOR QUANTITATIVE DETERMINATION OF AGOMELATINE IN COATED TABLETS
by: Fábio de Souza Barbosa, et al.
Published: (2017-12-01)

The burden of polypharmacy and pattern of comorbidities among chronic kidney disease patients in clinical practice
by: Olumuyiwa John Fasipe, et al.
Published: (2018-01-01)

Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder
by: Shek Ming Leung
Published: (2021-08-01)

Sub-Acute Oral Toxicity of a Novel Derivative of Agomelatine in Rats in a Sex-Dependent Manner
by: Qiushi Yang, et al.
Published: (2019-03-01)

Natural Psychoplastogens As Antidepressant Agents
by: Jakub Benko, et al.
Published: (2020-03-01)

Agomelatine Softens Depressive-Like Behavior through the Regulation of Autophagy and Apoptosis
by: Fengpei Chen, et al.
Published: (2021-01-01)

Cannot write session to /tmp/vufind_sessions/sess_viiq6f9p0qc5vqf4idsiuupi33